High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR

Bone Marrow Transplantation

Volumn 46, Issue 3, 2011, Pages 385-392

  Majhail, N S ^a,b   Bajorunaite, R ^c   Lazarus, H M ^d   Wang, Z ^c   Klein, J P ^c   Zhang, M J ^c   Rizzo, J D ^c  

^a CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

autologous HCT; overall survival; relapse; relative mortality

Indexed keywords

HEMOPOIETIC GROWTH FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SURVIVAL RATE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; SURVIVORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952532602     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.115     Document Type: Article

References (27)

1. Seshadri T, Keating A. Is there a role for autotransplants in AML in first remission? Biol Blood Marrow Transplant 2008; 15(1 Suppl): 17-20.
2. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIME-MA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
3. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978-2986. (Pubitemid 27444191)
4. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 2005; 128: 59-65.
5. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656. (Pubitemid 28550689)
6. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708. (Pubitemid 28105339)
7. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell trans-plantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480-2489. (Pubitemid 46655599)
8. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240. (Pubitemid 36988027)
9. Lazarus HM, Perez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132: 755-769. (Pubitemid 43381638)
10. Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM et al. Pre-transplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2006; 12: 204-216. (Pubitemid 43138015)
11. Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA et al. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 1306-1313.
12. Gorin NC, Labopin M, Meloni G, Korbling M, Carella A, Herve P et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991; 5: 896-904.
13. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215-4222. (Pubitemid 40720765)
14. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of followup. Lancet 2002; 359: 1309-1310.
15. Klein J, Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data. 2nd edn. Springer-Verlag: New York, 2003.
16. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
17. Andersen PK, Vaeth M. Simple parametric and nonparametric models for excess and relative mortality. Biometrics 1989; 45: 523-535. (Pubitemid 19165263)
18. Ramlou-Hansen H. Smoothing counting process intensities by means of kernel functions. Ann Stat 1983; 11: 453-466.
19. Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011-1016.
20. Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004; 10: 116-127. (Pubitemid 38145865)
21. Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2009; 147: 129-139.
22. Gorin NC, Labopin M, Blaise D, Reiffers J, Meloni G, Michallet M et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009; 27: 3987-3993.
23. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709. (Pubitemid 30412840)
24. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza Jr FR, Ringden O et al. Higher mortality after allogeneic peripheral blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-4880. (Pubitemid 46638610)
25. Khoury HJ, Loberiza FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY et al. Impact of post-transplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplanta-tion. Blood 2006; 107: 1712-1716. (Pubitemid 43242413)
26. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655-4664. (Pubitemid 36025282)
27. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony stimulating factor after allogeneic bone marrow transplanta-tion for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-423. (Pubitemid 41079769)